文献速递神经乳腺PETMRCT

18F-氟雌二醇(FES)脑PET在雌激素受体阳性乳腺癌合并已知或疑似脑转移患者评估中的应用

[18F]-Fluoroestradiol (FES) brain PET in the evaluation of patients with estrogen receptor positive breast cancer and known or suspected brain metastases.
PubMed 文献 · Eur J Radiol · 2024-10-15

回顾性纳入7例活检证实ER+乳腺癌且MRI怀疑新发、进展或复发脑转移的患者,行专用脑FES PET/CT或PET/MRI并与FDG PET及MRI比较。以病理和/或临床及MRI随访为金标准,15/16(94%)肿瘤病灶FES阳性,4/4(100%)放疗后改变病灶FES阴性;肿瘤FES-SUVR中位数6.0高于放疗后改变0.5(p<0.01)。FDG摄取在肿瘤病灶有增高趋势但未达统计学显著。作者认为FES脑PET是有前景的辅助手段,但受样本量小、回顾性设计及ER表达异质性可能性的限制,值得未来前瞻性临床试验。

要点

  • 肿瘤病灶FES阳性率15/16(94%),放疗后改变病灶FES阴性率4/4(100%)。
  • 肿瘤FES-SUVR中位数6.0高于放疗后改变0.5(p<0.01)。
  • FDG PET在肿瘤病灶有摄取增高趋势但未达统计学显著。

核心结论

  • 专用脑FES PET是有前景的辅助手段,但受样本量小、回顾性设计及ER表达异质性可能性的限制,值得未来前瞻性临床试验将专用脑FES PET/CT和PET/MRI纳入ER阳性乳腺癌脑转移患者的管理。

研究设计与样本

  • 回顾性研究,纳入7例活检证实ER+乳腺癌且MRI显示怀疑新发、进展或复发脑转移的患者,行专用脑FES PET/CT或PET/MRI,以病理和/或临床及MRI随访数据为金标准分类存活肿瘤与放疗后改变。

关键影像表现/征象

  • MRI定义的目标病灶中,肿瘤病灶FES阳性15/16(94%),放疗后改变病灶FES阴性4/4(100%)。
  • 肿瘤病灶FES-SUVR中位数6.0(范围2.8-9.1)高于放疗后改变0.5(范围0.3-0.7),p<0.01。
  • 肿瘤病灶FES-SUV中位数4.8(范围2.8-9.1)高于放疗后改变0.6(范围0.3-0.8),p<0.01。
  • 基于病灶分析的FDG-SUV和FDG-SUVR显示肿瘤病灶FDG摄取有增高趋势,但未达统计学显著。

诊断标准与关键数值

  • 以病理和/或临床及MRI随访数据为金标准分类存活肿瘤与放疗后改变。
  • FES阳性病灶:15/16(94%)肿瘤病灶为FES阳性;FES阴性病灶:4/4(100%)放疗后改变病灶为FES阴性。
  • 肿瘤FES-SUVR中位数6.0(2.8-9.1)vs 放疗后改变0.5(0.3-0.7),p<0.01;肿瘤FES-SUV中位数4.8(2.8-9.1)vs 放疗后改变0.6(0.3-0.8),p<0.01。
  • FDG-SUV和FDG-SUVR在肿瘤病灶有增高趋势但未达统计学显著。

临床应用与阅片要点

  • 专用脑FES PET/CT或PET/MRI可用于评估ER+乳腺癌患者MRI怀疑新发、进展或复发脑转移的病灶。
  • FES阴性可能有助于识别放疗后改变,但需结合病理和/或临床及MRI随访综合判断。
  • FDG PET在鉴别肿瘤与放疗后改变方面仅显示增高趋势但未达统计学显著。

局限性

  • 样本量小。
  • 回顾性研究。
  • 可能存在ER表达异质性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVE: Our purpose was to describe our initial institutional experience using dedicated brain [18F]-Fluoroestradiol (FES) PET/CT or PET/MRI in the management of patients with estrogen-receptor-positive (ER+) breast cancer brain metastases (BCBM), and compare to [18F]-Fluorodeoxyglucose (FDG) PET and MRI.

MATERIALS &amp; METHODS: Patients with biopsy-proven ER+ disease and MRI findings of suspected new, progressive, or recurrent BCBM were included in this retrospective study. Clinical and demographic data were collected. Dedicated brain FES PET/CT or PET/MRI was performed for clinical purposes. Maximum standardized uptake value (SUV) in MRI-defined target lesions and SUV ratio (SUVR, referencing normal-appearing parenchyma) were obtained. Pathology and/or clinical and MRI follow-up data were used as gold standard to classify viable neoplasm versus post-radiotherapy (RT) sequelae. Mann-Whitney tests were performed to compare subgroups.

RESULTS: Seven patients met inclusion criteria. 15/16 (94 %) lesions classified as neoplasm were FES-positive. 4/4 (100 %) lesions classified as RT sequelae were FES-negative. Median tumor FES-SUVR were higher than median RT-sequelae FES-SUVR (6.0 (2.8-9.1) versus 0.5 (0.3-0.7), p < 0.01), and similarly, median tumor FES-SUV were higher than median RT-sequelae FES-SUV (4.8 (2.8-9.1) versus 0.6 (0.3-0.8), p < 0.01). Lesion-based analysis of FDG-SUV and -SUVR demonstrated a trend for higher FDG avidity in lesions characterized as neoplasm; however, this did not reach statistical significance.

CONCLUSION: Dedicated FES brain PET represents a promising adjunct modality, noting limitations of small sample size, retrospective nature of our study, and the possibility of ER expression heterogeneity. Our findings merit future prospective clinical trials incorporating dedicated brain FES PET/CT and PET/MRI in the management of patients with ER-positive disease and BCBM.

来源:Eur J Radiol,查看原文。版权归原作者所有。

引用

  1. Ivanidze J, Sharbatdaran A, McCalla A, et al. [18F]-Fluoroestradiol (FES) brain PET in the evaluation of patients with estrogen receptor positive breast cancer and known or suspected brain metastases. Eur J Radiol. 2024. PMID: 39423781. doi:10.1016/j.ejrad.2024.111791

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。